NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.The second-generation Bruton tyrosine kinase (BTK) inhibitor also had a better safety profile than ibrutinib (Imbruvica; Pharmacyclics, Janssen), particularly with